Interim Report
1st Quarter 2005

May 10, 2005

Genmab A/S
Toldbodgade 33
DK-1253 Copenhagen K
CVR–no. 21 02 38 84

Dear Shareholder,

For the first quarter of 2005, Genmab reported a net loss of DKK 100.9 million (approximately USD 17.6 million) compared to a net loss of DKK 84.4 million (approximately USD 14.7 million) for the same period in 2004.

At March 31, 2005, Genmab had cash and marketable securities of DKK 1.102 billion (approximately USD 191.8 million).

In the first quarter of 2005, Genmab's research and development costs accounted for 84% of operating costs and were DKK 90.6 million (approximately USD 15.8 million) compared to DKK 84.7 million (approximately USD 14.7 million) in the first quarter of 2004. General and administrative expenses were DKK 17.4 million (approximately USD 3.0 million) compared to DKK 15.1 million (approximately USD 2.6 million in the corresponding period of 2004.

The net loss per share was DKK 3.37 (approximately USD 0.59) for the first quarter of 2005 compared to DKK 3.65 (approximately USD 0.63) for the first quarter of 2004.

Outlook

Genmab is maintaining its financial guidance for the year. We project a 2005 operating loss of DKK 495 to 535 million and a net loss in the range of DKK 465 to 505 million. The cash consumption is expected to be in the range of approximately DKK 360 to 400 million in 2005.

The estimates are subject to possible change primarily due to the timing and variation of clinical activities and related costs. The estimates also assume that no further agreements are entered into during 2005 that could materially affect the results.

Highlights

The highlights of the first quarter of 2005 included the following business and scientific achievements:

- HuMax-CD4 showed additional encouraging duration of response data from Phase II studies treating patients with mycosis fungoides (MF), a type of cutaneous T-cell lymphoma (CTCL). Subsequent to the balance sheet date, on April 20, 2005, it was announced that Genmab and the FDA had reached agreement on the design of the HuMax-CD4 pivotal study in CTCL under the Special Protocol Assessment process.

- Completion of enrolment in the HuMax-CD20 Phase I/II study to treat patients with chronic lymphocytic leukaemia (CLL).

- Genmab won the James D. Watson Helix Award in the international category for the company's achievements in 2004. The Helix Award honors biotechnology companies that display leadership in scientific innovation, company growth and corporate citizenship.

- As part of its Q1 results presentation in April, Amgen announced it had completed dosing in the AMG 714 Phase II rheumatoid arthritis study.

- Subsequent to the balance sheet date, on May 2, 2005, Genmab signed an agreement with Serono granting Serono exclusive worldwide rights to develop and commercialize Genmab's HuMax-TAC.

Product Pipeline

During the first quarter of 2005, we continued to build a broad portfolio of products in various stages of development. As per March 31, 2005, the clinical pipeline included four Phase II studies, one of which is being developed under an

agreement with our partner Amgen and five Phase I/II studies. Subsequent to the balance sheet date, one program has progressed into Phase III, pivotal study.

The following is an update on the status of each program.

HuMax-CD4
HuMax-CD4 is currently in development for the treatment of both cutaneous T-cell lymphoma (CTCL) and non-cutaneous T-cell lymphoma. In April 2005, Genmab and FDA reached agreement on the design of the HuMax-CD4 pivotal study in CTCL under the Special Protocol Assessment process. The study will be carried out under an FDA Fast Track designation.

Genmab has achieved positive results in Phase II studies using HuMax-CD4 to treat CTCL in both early stage patients and patients with late stage persistent CTCL who were refractory or intolerant to previous therapy.

In February 2005, Genmab announced additional encouraging duration of response data from the Phase II study treating patients with mycosis fungoides (MF), a type of CTCL. Data from all patients in the study showed a median response duration of more than 45 weeks (10.5 months). Furthermore, analysis of the time to response showed that 85% of the responding patients (11 out of 13) obtained clinical response within 8 weeks. Genmab has US Orphan Drug designation for HuMax-CD4 to treat MF patients.

HuMax-CD20
Antibodies in Genmab's HuMax-CD20 program target the CD20 antigen on B-cells. HuMax-CD20 is currently in three ongoing Phase I/II studies.

In December 2004, a body of safety and efficacy data from the Phase I/II study to treat follicular lymphoma was presented. In the 11 patients in the lower dose groups of 300 mg and 500 mg that were evaluable at the time, this data showed a 55% response rate. The study is ongoing and efficacy and safety results for all patients will be presented at a later date.

An additional Phase I/II study is currently underway employing HuMax-CD20 in the treatment of relapsed or refractory chronic lymphocytic leukaemia (CLL). In December 2004, the FDA awarded HuMax-CD20 a Fast Track designation for the treatment of CLL patients who have failed fludarabine therapy. In March 2005, Genmab announced that enrolment of patients was completed for this Phase I/II study in CLL.

Following FDA's acceptance of Genmab's IND in December 2004, we have initiated a Phase I/II dose escalation trial for HuMax-CD20 to treat patients with active RA who have failed one or more disease modifying anti-rheumatic drugs (DMARDs).

HuMax-EGFr
HuMax-EGFr is a human antibody that targets the Epidermal Growth Factor Receptor, a molecule found in abundance on the surface of many cancer cells. An open label Phase I/II dose escalation study using HuMax-EGFr to treat patients suffering from head and neck cancer is currently ongoing. Data from the study released in December 2004 showed encouraging efficacy. Safety data from the ongoing study indicates a favourable safety profile with no patients experiencing dose limiting toxicity up to the highest dose of 8 mg/kg.

AMG 714
AMG 714, formerly known as HuMax-IL15, is being developed under an agreement with Amgen to treat inflammatory, autoimmune diseases. Amgen has taken responsibility for further development of AMG 714, and has recently completed the dosing in the AMG 714 Phase II study to treat patients with RA. AMG 714 could

potentially be used for the treatment of other inflammatory diseases such as psoriasis or inflammatory Bowel disease.

In October 2004, interim data was presented at the American College of Rheumatology annual meeting from the first 110 patients in the ongoing Phase II RA study. At week 14, 57% of patients in the highest dose group (280 mg) demonstrated an ACR20 response compared to 35% in the placebo group.

HuMax-Inflam
HuMax-Inflam is a high-affinity human antibody in development to treat inflammatory conditions. HuMax-Inflam is being developed in collaboration with Medarex. In December 2004, Genmab and Medarex announced encouraging safety and efficacy data from a Phase I/II study using HuMax-Inflam in a range of doses to treat patients suffering from an undisclosed autoimmune disease.

Pre-Clinical Programs
Genmab's named pre-clinical programs include HuMax-HepC, to potentially treat Hepatitis C virus reinfection after liver transplantation and HuMax-TAC. In May 2005, Genmab and Serono signed an agreement, granting Serono exclusive worldwide rights to develop and commercialize HuMax-TAC. HuMax-TAC may have therapeutic potential in the treatment of T-cell mediated diseases, including inflammation and autoimmune disease. Serono is responsible for all future development costs. Genmab will receive an upfront payment and is entitled to potential milestone payments and royalties on sales from any eventual commercialization of the product.

Consolidated Key Figures

The following key figures and financial ratios have been prepared on a consolidated basis. The financial ratios have been calculated in accordance with the recommendations of the Association of Danish Financial Analysts. Key figures comply with the requirements under the Danish Financial Statements Act and the IFRS. All key figures and financial ratios are in conformity with the current accounting policies. The figures for the first quarter of 2004 have been adjusted to reflect the changes in accounting policies as per January 1, 2005. The figures have been stated in thousands, except for the financial ratios.

	1st quarter of 2005 DKK'000	1st quarter of 2004 DKK'000	1st quarter of 2005 USD'000	1st quarter of 2004 USD'000
Income Statement				
Research and development costs	(90,590)	(84,716)	(15,765)	(14,743)
General and administrative expenses	(17,397)	(15,115)	(3,028)	(2,630)
Operating loss	(107,987)	(99,831)	(18,793)	(17,373)
Net financial income	7,041	15,469	1,225	2,692
Net loss	(100,946)	(84,362)	(17,568)	(14,681)
Balance Sheet				
Cash and marketable securities	1,101,882	985,691	191,755	171,535
Total assets	1,209,785	1,112,215	210,533	193,553
Shareholders' equity	1,099,776	1,017,849	191,388	177,131
Share capital	30,055	23,278	5,230	4,051
Investments in tangible fixed assets	1,573	7,836	274	1,364
Cash Flow Statement				
Cash flow from operating activities	(73,419)	(67,830)	(12,777)	(11,804)
Cash flow from investing activities	43,642	21,153	7,594	3,681
Cash flow from financing activities	12,759	13,542	2,220	2,356
Cash and cash equivalents	402,681	275,882	70,077	48,010
Financial Ratios (in DKK / USD)				
Basic and diluted net loss per share	(3.37)	(3.65)	(0.59)	(0.63)
Period-end share market price	111.16	84.90	19.34	14.77
Price / book value	3.04	1.94	3.04	1.94
Shareholders' equity per share	36.59	43.73	6.37	7.61
Average number of employees	213	198	213	198
Number of employees at the end of the period	211	198	211	198

Financial Review

The Interim Report for the first quarter of 2005 is prepared on a consolidated basis for the Genmab Group. The financial statements are published in Danish Kroner (DKK). Solely for the convenience of the reader, this Interim Report contains a conversion of certain DKK amounts into US Dollars (USD) at a specified rate. These converted amounts should not be construed as representations that the DKK amounts actually represent such USD amounts or could be converted into USD at the rate indicated or at any other rate.

Unless otherwise indicated, conversion herein of financial information into USD has been made using the Danish Central Bank's spot rate on March 31, 2005, which was USD 1.00 = DKK 5.7463.

Operating Loss

The Group's operating loss for the first quarter of 2005 was DKK 108.0 million compared to DKK 99.8 million for the similar quarter of 2004.

Research and development costs increased from DKK 84.7 million in the first quarter of 2004 to DKK 90.6 million for the first quarter of 2005. This increase is a consequence of the Group's increasing activities and extensive costs for manufacturing of antibodies.

General and administrative expenses were DKK 17.4 million in the first quarter of 2005 compared to DKK 15.1 million in the similar period of 2004.

The operating loss for the first quarter of 2005 includes warrant compensation expenses totalling

DKK 4.7 million compared to DKK 0.8 million for the first quarter of 2004. Please refer to the section on adoption of IFRS 2.

Financial Income
Net financial income for the first quarter of 2005 was DKK 7.0 million compared to DKK 15.5 million in the same period of 2004. Net financial income in the first quarter of 2004 was positively impacted by a rather significant strengthening of the USD against the DKK, primarily affecting the USD portion of our investment portfolio.

Net Loss
Net loss for the first quarter of 2005 was DKK 100.9 million compared to DKK 84.4 million in the first quarter of 2004. The change is primarily due to higher research and development costs and lower net financial income in 2005 compared to 2004.

Cash Flow
As of March 31, 2005, the balance sheet reflects cash, cash equivalents and marketable securities of DKK 1.102 billion compared to DKK 1.158 billion as of December 31, 2004. This represents a cash consumption of DKK 56 million.

The cash flow for the first quarter of 2005 is in line with our expectations. The cash flow is mainly driven by the operating activities, which account for DKK 73.4 million compared to DKK 67.8 million in the same period of 2004. This was reduced by proceeds from exercise of warrants of DKK 14.8 million compared to DKK 14.9 million in the same period of 2004.

Balance Sheet
As of March 31, 2005, total assets were DKK 1.210 billion compared to DKK 1.272 billion at the end of 2004.

Shareholders equity, as of March 31, 2005, equalled DKK 1.100 billion compared to DKK 1.181 billion at the end of 2004. On March 31, 2005, the Group's equity ratio was 91% which is slightly lower than the 93% at the end of 2004.

Subsequent Events

On April 20, 2005, it was announced that Genmab and FDA had reached agreement on the design of the HuMax-CD4 pivotal study in CTCL under the Special Protocol Assessment process (SPA). The pivotal study, which is carried out under an FDA Fast Track designation, includes patients with the most common form of CTCL, mycosis fungoides (MF), who are refractory to or intolerant of Targretin® and one other standard therapy, and consists of two stages. As Genmab has changed manufacturer for HuMax-CD4 in order to prepare for potential commercial launch, Genmab has agreed with the FDA to treat a total of 18 patients at three doses (4 mg/kg, 8 mg/kg, and 14 mg/kg) prior to treating the remaining 70 patients in a randomized manner at the two higher doses.

On May 2, 2005, it was announced that Genmab has signed an agreement with Serono under which Genmab grants Serono exclusive worldwide rights to develop and commercialize Genmab's HuMax-TAC. HuMax-TAC is currently in pre-clinical trials. Under the agreement, Genmab will receive an upfront payment of USD 2 million and is entitled to potential milestone payments of up to USD 38 million and royalties on sales from any eventual commercialization of the product. Serono will be responsible for all future development costs for HuMax-TAC.

No other significant events have occurred since the balance sheet date which could significantly affect the financial statements as of March 31, 2005.

Additional information:

Helle Husted
Director, Investor Relations
Telephone +45 33 44 77 30

The forward looking statements contained in this Interim Report are subject to risks and uncertainties, so that the actual results may differ materially from those anticipated by the statements. These and certain other important factors affecting the business of Genmab A/S are described in the company's previously issued Annual Report and Private Placement Memorandum.

Directors' and Management's Statement on the Interim Report

The Board of Directors and Management have today considered and adopted the Interim Report of Genmab A/S for the period January 1 to March 31, 2005.

The Interim Report is prepared in accordance with the Copenhagen Stock Exchange's financial reporting requirements for listed companies. The Interim Report is in compliance with International Accounting Standard No. 34 (IAS 34), "Interim Financial Reporting", the Danish Financial Statements Act and the additional Danish financial reporting requirements for listed companies.

We consider the applied accounting policies to be appropriate and, in our opinion, the Interim Report gives a true and fair view of the assets and liabilities, financial position, results of operation and cash flows of the Group.

Copenhagen, May 10, 2005

Management

Lisa N. Drakeman	Claus Juan Møller-San Pedro	Jan van de Winkel

Board of Directors

Michael B. Widmer (Chairman)	Lisa N. Drakeman	Irwin Lerner
Anders Gersel Pedersen	Karsten Havkrog Pedersen	Ernst H. Schweizer

Income Statement for the First Quarter of 2005

	1st quarter of 2005 DKK'000	1st quarter of 2004 DKK'000	1st quarter of 2005 USD'000	1st quarter of 2004 USD'000
Research and development costs	(90,590)	(84,716)	(15,765)	(14,743)
General and administrative expenses	(17,397)	(15,115)	(3,028)	(2,630)
Operating loss	**(107,987)**	**(99,831)**	**(18,793)**	**(17,373)**
Financial income	18,170	26,282	3,162	4,574
Financial expenses	(11,129)	(10,813)	(1,937)	(1,882)
Net loss	**(100,946)**	**(84,362)**	**(17,568)**	**(14,681)**
Basic and diluted net loss per share (in DKK / USD)	(3.37)	(3.65)	(0.59)	(0.63)
Weighted average number of ordinary shares outstanding during the period - basic and diluted	29,914,236	23,143,094	29,914,236	23,143,094

Balance Sheet – Assets

	Note	March 31, 2005 DKK'000	December 31, 2004 DKK'000	March 31, 2004 DKK'000	March 31, 2005 USD'000	December 31, 2004 USD'000	March 31, 2004 USD'000
Licenses and rights		5,976	10,725	26,776	1,040	1,866	4,660
Total intangible fixed assets		**5,976**	**10,725**	**26,776**	**1,040**	**1,866**	**4,660**
Leasehold improvements		13,816	15,506	19,322	2,404	2,698	3,363
Equipment, furniture and fixtures		33,597	36,236	42,847	5,847	6,306	7,456
Fixed assets under construction		6,449	5,611	5,971	1,122	976	1,039
Total tangible fixed assets		**53,862**	**57,353**	**68,140**	**9,373**	**9,980**	**11,858**
Other securities and equity interests		3,066	5,726	5,726	534	996	996
Non-current receivables		6,049	5,950	-	1,053	1,035	-
Total financial fixed assets		**9,115**	**11,676**	**5,726**	**1,587**	**2,031**	**996**
Total non-current assets		**68,953**	**79,754**	**100,642**	**12,000**	**13,877**	**17,514**
Other receivables		32,836	24,173	20,915	5,714	4,207	3,640
Prepayments		6,114	9,553	4,967	1,064	1,662	864
Total receivables		**38,950**	**33,726**	**25,882**	**6,778**	**5,869**	**4,504**
Marketable securities	2	**699,201**	**738,862**	**709,809**	**121,678**	**128,580**	**123,525**
Cash and cash equivalents		**402,681**	**419,566**	**275,882**	**70,077**	**73,015**	**48,010**
Total current assets		**1,140,832**	**1,192,154**	**1,011,573**	**198,533**	**207,464**	**176,039**
Total assets		**1,209,785**	**1,271,908**	**1,112,215**	**210,533**	**221,341**	**193,553**

Balance Sheet – Shareholders' Equity and Liabilities

	Note	March 31, 2005	December 31, 2004	March 31, 2004	March 31, 2005	December 31, 2004	March 31, 2004
		DKK'000	DKK'000	DKK'000	USD'000	USD'000	USD'000
Share capital		30,055	29,752	23,278	5,230	5,178	4,051
Share premium		2,605,748	2,591,311	2,102,627	453,465	450,953	365,910
Equity reserve		4,804	4,528	4,876	836	788	849
Reserve for share-based payment		14,135	9,415	2,023	2,460	1,638	352
Accumulated deficit		(1,554,966)	(1,454,020)	(1,114,955)	(270,603)	(253,036)	(194,031)
Shareholders' equity		**1,099,776**	**1,180,986**	**1,017,849**	**191,388**	**205,521**	**177,131**
Lease liability		17,884	20,960	15,444	3,112	3,648	2,688
Total non-current liabilities		**17,884**	**20,960**	**15,444**	**3,112**	**3,648**	**2,688**
Current portion of payable technology rights		-	-	11,916	-	-	2,074
Current portion of lease liability		9,180	8,044	5,368	1,598	1,400	934
Accounts payable		24,415	15,768	14,999	4,249	2,744	2,610
Other liabilities		58,530	46,150	46,639	10,186	8,028	8,116
Total current liabilities		**92,125**	**69,962**	**78,922**	**16,033**	**12,172**	**13,734**
Total liabilities		**110,009**	**90,922**	**94,366**	**19,145**	**15,820**	**16,422**
Total shareholders' equity and liabilities		**1,209,785**	**1,271,908**	**1,112,215**	**210,533**	**221,341**	**193,553**

Statement of Cash Flow

	1st quarter of 2005 DKK'000	1st quarter of 2004 DKK'000	1st quarter of 2005 USD'000	1st quarter of 2004 USD'000
Net loss	**(100,946)**	**(84,362)**	**(17,568)**	**(14,681)**
Reversal of financial items, net	(7,041)	(15,469)	(1,225)	(2,692)
Adjustments for non-cash transactions:				
Depreciation and amortization	10,122	19,961	1,761	3,474
Warrant compensation expenses	4,720	823	821	143
Changes in current assets and liabilities:				
Other receivables	(9,017)	2,125	(1,569)	370
Prepayments	3,456	(2,758)	601	(480)
Accounts payable and other liabilities	19,203	(3,754)	3,342	(653)
Cash flow from operating activities before financial items	**(79,503)**	**(83,434)**	**(13,837)**	**(14,519)**
Net financial receivables	6,084	15,604	1,060	2,715
Cash flow from operating activities	**(73,419)**	**(67,830)**	**(12,777)**	**(11,804)**
Purchase of property, plant and equipment	(136)	(2,618)	(24)	(456)
Sale of property, plant and equipment	-	120	-	21
Marketable securities bought	(190,115)	(210,137)	(33,085)	(36,569)
Marketable securities sold	233,893	233,788	40,703	40,685
Cash flow from investing activities	**43,642**	**21,153**	**7,594**	**3,681**
Warrants exercised	14,793	14,874	2,574	2,588
Costs related to issuance of shares	(53)	(30)	(9)	(5)
Paid installments on lease liabilities	(1,981)	(1,302)	(345)	(227)
Cash flow from financing activities	**12,759**	**13,542**	**2,220**	**2,356**
Decrease in cash and cash equivalents	**(17,018)**	**(33,135)**	**(2,963)**	**(5,767)**
Cash and cash equivalents at the beginning of the period	419,566	308,916	73,015	53,759
Exchange rate adjustment of cash	133	101	25	18
Cash and cash equivalents at the end of the period	**402,681**	**275,882**	**70,077**	**48,010**
Cash and cash equivalents include:				
Bank deposits and petty cash	373,693	227,091	65,032	39,520
Restricted bank deposits	28,988	30,527	5,045	5,312
Short term marketable securities	-	18,264	-	3,178
	402,681	**275,882**	**70,077**	**48,010**

Statement of Shareholders' Equity

	Number of shares	Share capital	Share premium	Equity reserve	Reserve for share-based payment	Accumulated deficit	Shareholders' equity	Shareholders' equity
		DKK'000	DKK'000	DKK'000	DKK'000	DKK'000	DKK'000	USD'000
December 31, 2003	**22,980,534**	**22,981**	**2,088,080**	**4,766**	**0**	**(1,029,393)**	**1,086,434**	**189,067**
Effects of change in accounting policies, IFRS 2 - warrant compensation expenses					1,200	(1,200)	-	-
December 31, 2003, adjusted	**22,980,534**	**22,981**	**2,088,080**	**4,766**	**1,200**	**(1,030,593)**	**1,086,434**	**189,067**
Exercise of warrants	297,599	297	14,577				14,874	2,588
Expenses related to exercise of warrants			(30)				(30)	(5)
Adjustment of foreign currency fluctuations on subsidiaries				110			110	19
Loss for the period, previously reported						(83,539)	(83,539)	(14,538)
Effect of change in accounting policies, IFRS 2 - warrant compensation expenses					823	(823)	-	-
March 31, 2004, adjusted	**23,278,133**	**23,278**	**2,102,627**	**4,876**	**2,023**	**(1,114,955)**	**1,017,849**	**177,131**
Capital increase	5,623,000	5,623	472,332				477,955	83,176
Exercise of warrants	851,230	851	48,664				49,515	8,617
Expenses related to capital increase			(32,312)				(32,312)	(5,623)
Adjustment of foreign currency fluctuations on subsidiaries				(348)			(348)	(61)
Loss for the period, previously reported						(331,673)	(331,673)	(57,719)
Effect of change in accounting policies, IFRS 2 - warrant compensation expenses					7,392	(7,392)	-	-
December 31, 2004, adjusted	**29,752,363**	**29,752**	**2,591,311**	**4,528**	**9,415**	**(1,454,020)**	**1,180,986**	**205,521**
Exercise of warrants	303,041	303	14,490				14,793	2,574
Expenses related to exercise of warrants			(53)				(53)	(9)
Warrant compensation expenses					4,720		4,720	821
Adjustment of foreign currency fluctuations on subsidiaries				276			276	48
Loss for the period						(100,946)	(100,946)	(17,567)
March 31, 2005	**30,055,404**	**30,055**	**2,605,748**	**4,804**	**14,135**	**(1,554,966)**	**1,099,776**	**191,388**

Notes to the Financial Statements

1. Accounting Policies

The Interim Report has been prepared in accordance with the Copenhagen Stock Exchange's financial reporting requirements for listed companies. The Interim Report is in compliance with International Accounting Standard No. 34 (IAS 34), "Interim Financial Reporting".

New and Improved Standards from IASB
Effective from January 1, 2005, the Group has adopted the new International Financial Reporting Standards issued by the International Accounting Standards Board, as well as the updated standards arising from the IASB Improvement Project. The adoption of these new and improved standards has affected the financial reporting of Genmab as follows:

IFRS 2, Share-Based Payment Transactions
In line with the transitional provisions of IFRS 2, this new standard has been applied to all warrants granted after November 7, 2002. The adoption has increased the net loss for the first quarter of 2005 by DKK 4,720 thousand. The effect on the results for prior periods has been recorded in equity and comparative figures have been adjusted accordingly. The effect on the first quarter of 2004 was an expense of DKK 823 thousand. The adoption of IFRS 2 has not affected the consolidated equity as per any of the dates presented, except for a reclassification within the equity accounts to reflect the reserve for share-based payment.

IAS 27, Consolidated Financial Statements and Accounting for Investments in Subsidiaries
The adoption of the revised IAS 27 has changed the accounting for subsidiaries in the separate financial statements of the parent company Genmab A/S from the equity method to measurement at cost. The separate financial statements of the parent company are not disclosed in this Interim Report. The adoption of the revised IAS 27 has not affected the reported results or equity of the Group.

The adoption of other new or improved standards issued by the IASB has not affected the financial reporting of the Group for any periods presented in this Interim Report.

Except for the adoption of the new and improved standards issued by the IASB, the accounting policies used for the Interim Report are consistent with the accounting policies used in the company's latest Annual Report, which was prepared in accordance with the IFRS, the provisions of the Danish Financial Statements Act for listed companies in accounting class D, the Danish Accounting Standards, and the Copenhagen Stock Exchange's financial reporting requirements for listed companies.

The Interim Report has been prepared in Danish Kroner (DKK), which is the functional currency of the company and the Group.

The most significant items of the Group's accounting policies are:

Consolidated Financial Statements
The consolidated financial statements include Genmab A/S (the parent company), Genmab B.V., Genmab, Inc., and Genmab Ltd. (collectively referred to as the Genmab Group).

Notes to the Financial Statements

1. Accounting Policies (continued)

Stock-Based Compensation
For warrants granted after November 7, 2002, the Group applies IFRS 2, according to which the fair value of the warrants at grant date is recognized as an expense in the income statement over the vesting period. A corresponding amount is recognized in a separate reserve under equity. Warrants granted prior to November 7, 2002 are not comprised by IFRS 2. The Group accounts for such warrants by use of the intrinsic value method for employees and the Board of Directors and the fair value method for non-employee consultants.

Marketable Securities
Marketable securities consist of investments in securities with a maturity greater than three months at the time of purchase. The securities can be readily purchased and sold using established markets. When sold, the cost of marketable securities is determined based on the "first-in first-out" principle. Marketable securities are classified as "financial assets at fair value through profit or loss". Fair value equals the listed price. Realized and unrealized gains and losses (including unrealized foreign exchange rate gains and losses) are recognized in the income statement as financial items. Transactions are recognized at trade date.

Cash and Cash Equivalents
Cash and cash equivalents comprise cash, bank deposits and marketable securities with a maturity of three months or less on the date of acquisition. Cash and cash equivalents are measured at fair value.

Segment Reporting
The Group is managed and operated as one business unit. The entire Group is managed by a single management team reporting to the Chief Executive Officer. No separate lines of business or separate business entities have been identified with respect to any product candidates or geographical markets. Accordingly, the company has concluded that it is not relevant to disclose segment information on business segments or geographical markets.

Reconciliation from IFRS to US GAAP
The Interim Report includes a reconciliation of the reported net result under IFRS to the corresponding net result under US GAAP.

Notes to the Financial Statements

2. Marketable Securities

The Group has classified all investments as short-term since it has the intent and ability to sell and redeem them within a year.

	March 31, 2005	December 31, 2004	March 31, 2004	March 31, 2005	December 31, 2004	March 31, 2004
	DKK'000	DKK'000 (full year)	DKK'000	USD'000	USD'000 (full year)	USD'000
Cost at the beginning of the period	749,159	744,584	744,584	130,372	129,576	129,576
Additions for the period	190,115	1,163,346	210,137	33,085	202,451	36,569
Disposals for the period	(235,258)	(1,158,771)	(233,776)	(40,941)	(201,655)	(40,683)
Cost at the end of the period	**704,016**	**749,159**	**720,945**	**122,516**	**130,372**	**125,462**
Adjustment to fair value at the beginning of the period	(10,297)	(17,724)	(17,724)	(1,792)	(3,084)	(3,084)
Adjustment to fair value for the period	5,482	7,427	6,588	954	1,292	1,147
Adjustment to fair value at the end of the period	**(4,815)**	**(10,297)**	**(11,136)**	**(838)**	**(1,792)**	**(1,937)**
Net book value at the end of the period	**699,201**	**738,862**	**709,809**	**121,678**	**128,580**	**123,525**

3. Warrants

Warrant Scheme

Genmab A/S has established warrant schemes as an incentive for all company employees, including those in our subsidiaries, members of the Board of Directors and members of the executive management as well as certain external consultants with a long-term relationship with us. All employees to date have been granted warrants in connection with their employment.

Warrants Granted from August 2004

Under the most recent warrant scheme, effective from August 2004, warrants can be exercised from one year after the grant date. The warrant holder may as a general rule only exercise 25% of the warrants granted per full year of employment or affiliation with Genmab after the grant date. However, the warrant holder will be entitled to exercise all warrants granted regardless of termination of the relationship in instances where the employment or consultancy relationship is terminated without the warrant holder having given the company a good reason to do so. All warrants lapse at the tenth anniversary of the grant date.

Notes to the Financial Statements

3. Warrants (continued)

Warrants Granted prior to August 2004
Half of the warrants granted under the preceding warrant schemes can be exercised one year after the grant date with the other half exercisable two years after the grant date. The exercise period lasts for three years from the date when a warrant first becomes exercisable. If the warrants are not exercised within these periods, they lapse.

The exercise of warrants is not conditional upon continued employment or affiliation with Genmab. However, if the warrant holder exercises warrants, then upon the conclusion of employment or affiliation, the holder is obligated to offer to sell a specified percentage of shares issued back to the company. The sell back clause is not applicable in the event of termination as a result of the company's breach of the employment or affiliation contract. The sell back clause defines the percentage of shares that the holder is required to offer to sell back to the company.

The repurchase price to be paid for the shares by the company in these instances is the warrant holder's original exercise price. Accordingly, the warrant holder will not be able to profit on shares sold back to the company.

Warrant Activity
As of March 31, 2005, the Board of Directors has been authorized to grant a total of 6,021,263 warrants since the company's inception.

No warrants were granted during the first quarter of 2005. A total of 303,041 warrants have been exercised during the period, resulting in proceeds to the company of DKK 14,793 thousand. 132,901 warrants have expired without being exercised. As of March 31, 2005, 2,749,230 warrants with a weighted average exercise price of DKK 118.61 were outstanding under the preceding warrant schemes and 845,875 warrants with a weighted average exercise price of DKK 87.20 were outstanding under the August 2004 warrant scheme. As of March 31, 2004, a total of 4,136,700 warrants with a weighted average exercise price of DKK 108.61 were outstanding.

Compensation expenses under IFRS 2, "Share-based Payment Transactions" totaled DKK 4,720 thousand for the first quarter of 2005, compared to DKK 823 thousand for the first quarter of 2004.

Notes to the Financial Statements

4. Internal Shareholders

The following table sets forth certain information regarding the beneficial ownership of the issued share capital and the outstanding warrants by the members of the Board of Directors and the management:

	Number of ordinary shares owned	Number of warrants held
Board of directors		
Lisa N. Drakeman	473,540	412,500
Ernst H. Schweizer	194,840	72,000
Irwin Lerner	25,000	40,000
Michael B. Widmer	-	70,000
Karsten Havkrog Pedersen	-	35,000
Anders Gersel Pedersen	-	35,000
	693,380	**664,500**
Management		
Lisa N. Drakeman, see above	-	-
Jan van de Winkel	142,500	245,000
Claus Juan Møller-San Pedro	332,415	142,500
	474,915	**387,500**
Total	**1,168,295**	**1,052,000**

5. Reconciliation from IFRS to US GAAP for the First Quarter of 2005

The financial statements of the company are prepared in accordance with IFRS, which differ in certain aspects from US GAAP.

Comprehensive Income
Statement of Financial Accounting Standards (SFAS) No. 130, "Reporting Comprehensive Income," establishes US GAAP for the reporting and display of comprehensive income and its components in financial statements. Comprehensive income, which is a component of shareholders' equity, includes all unrealized gains and losses (including exchange rate gains and losses) on debt and equity securities classified as "Available-for-sale." Such securities would be classified as marketable securities in the financial statements under US GAAP and such unrealized gains and losses would be included in a separate statement in order to determine comprehensive income.

In accordance with IFRS, the company classifies such securities as marketable securities. Unrealized gains and losses (including exchange rate adjustments) are included in the income statement as financial items and in shareholders' equity as part of the accumulated deficit.

Notes to the Financial Statements

5. Reconciliation from IFRS to US GAAP for the First Quarter of 2005 (continued)

Warrant Compensation Expenses
Under IFRS, the fair value of warrants granted shall be recognized as an expense in the income statement with a corresponding entry in shareholders' equity. SFAS No. 123R, "Share-Based Payment (revised)" includes similar requirements, but as the effective date for this revised standard has not been reached yet, and accordingly, this standard has not been adopted, no similar requirement currently exists under US GAAP.

Application of US GAAP would have affected net loss for the periods ended March 31, 2005 and 2004 to the extent described below. Application of US GAAP would not have affected shareholders' equity as of any date for which financial information is presented herein.

	1st quarter of 2005 DKK'000	1st quarter of 2004 DKK'000	1st quarter of 2005 USD'000	1st quarter of 2004 USD'000
Net loss according to IFRS	**(100,946)**	**(84,362)**	**(17,568)**	**(14,681)**
Revaluation of marketable securities concerning measurement to market value	(1,251)	(3,792)	(218)	(660)
Reversed unrealized exchange rate (gain) / loss on marketable securities	(4,876)	(2,369)	(849)	(412)
Reversed warrant compensation expenses	4,720	823	821	143
Net loss according to US GAAP	**(102,353)**	**(89,700)**	**(17,814)**	**(15,610)**
Weighted average number of ordinary shares outstanding during the period - basic and diluted	29,914,236	23,143,094	29,914,236	23,143,094
Basic and diluted net loss per share according to US GAAP (in DKK / USD)	(3.42)	(3.88)	(0.60)	(0.67)
Net loss according to US GAAP	**(102,353)**	**(89,700)**	**(17,814)**	**(15,610)**
Other Comprehensive income:				
Unrealized gain / (loss) from marketable securities	1,251	3,792	218	660
Adjustment of foreign currency fluctuations in subsidiaries	276	110	48	19
Unrealized exchange rate gain / (loss) on marketable securities	4,876	2,369	849	412
Comprehensive income	**(95,950)**	**(83,429)**	**(16,699)**	**(14,519)**